Income · Stocks to Consider and Updates

Total Reports 4th Quarter Results: Increases Dividend

French integrated energy giant Total SA (NYSE: TOT - $54.77) reported adjusted net profit rose in the fourth quarter to $3.16 billion from $2.87 billion a year earlier, largely as a result of increased production volumes and reduced costs. On a per share basis, the company said it earned $1.17 compared to $1.10 last year and in… Continue reading Total Reports 4th Quarter Results: Increases Dividend

Income · Stocks to Consider and Updates

ALPS Sector Dividend Dogs – Update

The investment of the ALPS Sector Dividend Dogs exchange traded fund (NYSE: SDOG - $42.62) seeks investment results that closely replicates, before fees and expenses, the performance of the S-Network-Sector Dividend Dogs Index. The underlying index generally consists of 50 stocks on each annual reconstitution date, which is the third Friday of December each year.… Continue reading ALPS Sector Dividend Dogs – Update

Conservative · Stocks to Consider and Updates

3M Boosts Dividend

Industrial conglomerate 3M Co. (NYSE: MMM - $202.03) said its board boosted its quarterly dividend by 6% to $1.44 per share from $1.36. The annual payout based on the new dividend rate will be $5.76 per share, yielding about 2.8%. The quarterly dividend is payable March 12 to shareholders registered on Feb. 15. 3M has increased its dividend for 61 consecutive… Continue reading 3M Boosts Dividend

Aggressive · Stocks to Consider and Updates

Cerner Reports in Line; Initiates Dividend

Health information services provider Cerner Corp. (NASDAQ: CERN - $57.99) reported fourth quarter revenue of $1.366 billion, an increase of 4% compared to the fourth quarter of 2017, but about 2% less than analysts were expecting. Adjusted net earnings for the period was $208.1 million, compared to $195.7 million a year ago.  Adjusted earnings per share was in… Continue reading Cerner Reports in Line; Initiates Dividend

Aggressive · Stocks to Consider and Updates

Gilead Misses Profit Estimates; Hikes Dividend

Forrest City, California biotech Gilead Sciences, Inc. (NASDAQ: GILD - $70.05) reported fourth-quarter earnings results that fell short of Wall Street estimates as sales of its flagship hepatitis C drugs continued to slide. Revenue decreased to $5.80 billion from $5.95 billion a year ago but beat the analyst consensus of $5.52 billion. Sales of Gilead's HIV drugs rose to $4.1 billion from $3.4… Continue reading Gilead Misses Profit Estimates; Hikes Dividend